HDAC9 and inflammatory bowel disease: Since the recent FDA approval of the first HDAC inhibitor (Vorinostat) to treat cutaneous T-cell lymphoma, other inhibitory compounds have been proposed for the treatment of other cancers but also disorders such as inflammatory bowel diseases (IBD)5,6.